TP53 and cancer: In addition, AS may significantly alter the coding region of drug targets, thereby leading to increased drug resistance in some cancer therapies31, such as BCR-ABL splice variant, imatinib resistance; BCL2-Like 11 (BIM or BCL2L11) splice variant and TKI resistance; BRCA splice variants leading to PARP inhibitor or cytotoxic drug resistance; and TP53 splice variants and cisplatin resistance32.